Focus:
CBAK is best upside volatility in pre mkt…..
Anticipating another pickup back above .60 on news with FCPG…ongoing support at .55……Reminder highly profitable….Recent acquistion news also.
ANX faded a little into dayend, however closed at 3.10…..Recall entry at 3.11….Look for increasing volatility above 3….Reminding on FDA decision Sept…..strong cash 1.69pr shr…..
Recall emphasis on article below….
5 Dirt Cheap Biotech Stocks Poised to Tripleat Seeking Alpha(Tue, Jun 28)
5-10
RITT best % ….. up 2.10…..
RiT to Provide its IIM Solution for Datacenter Management to Global Financial InstitutionPR Newswire(Thu 8:00AM EDT)
3-5
Caught wiff of a chart/stock worth examining SSIE…..While most other otcs lagging this summer, notice general trending in June….Goldman has pretty good batting avg…
SunSi Energies, Inc. (“SunSi”), (OTCQB:SSIE), announced today that Goldman Small Cap Research (“Goldman Research”), a stock market research firm focused on the small cap and micro cap sectors, had initiated coverage on SunSi on May 9, 2011; and that Goldman Research had put a six-month price target on SunSi stock at $6.00 per share, and forecast a $12.00 per share price target by the end of 2012.
David Natan, SunSi’s Chief Executive Officer, stated, “We believe our stock price is significantly undervalued. The conclusions reached in this research report should help give us some additional visibility. We continue to execute our business plan, are now profitable, and expect to generate increasing profitability in future. We strongly believe that our business plan of acquiring trichlorosilane (TCS) production facilities and distribution rights, and growing those facilities both organically and through expansion, is the best way to capitalize on the most profitable segment of the solar value chain.”
SunSi Significantly Improves Liquidity With $5.0 Million in New Funding InitiativesGlobeNewswire(Wed, Jun 22)
Maintain focus on COOL following turnaround / ongoing strength….We disussed to debate this below 3……
Silver play GPL flexing at 3.45…..Has been rebuilding solid from upper 2s the last month……
2-3
SIRI continues to trend from 1.95….up .04 at 2.13…….
1-2
CBAK up .26….up .14….up .19…providing best volatility
China BAK Successfully Passes Samsung Factory AuditPR Newswire(Thu 6:30AM EDT)
Recall discussions on PLSB recent strength….Gaining market share on nutritional beverage mkts
Pulse Beverage Appoints Noted Industry Executive Paddy Sheya as Vice President and National Sales ManagerMarketwire(Tue, Jun 21) Pulse Beverage Appoints Internationally Acclaimed Nutrition Expert Dr. Pam Peeke to Advisory BoardMarketwire(Thu, Jun 16) Pulse Beverage Moving Quickly to Ensure All-Natural, Reduced Calorie Cabana(TM) Brand Lemonade on Shelves for SummerMarketwire(Tue, May 31) Pulse Beverage Corporation Announces NBT Equity Group Research Report by Tobin SmithMarketwire(Tue, May 24)
Press Release Source: First China Pharmaceutical Group, Inc. On Thursday June 30, 2011, 9:00 am
HONG KONG–(Marketwire – 06/30/11) – First China Pharmaceutical Group, Inc. (OTC.BB:FCPG – News) (“First China” or the “Company”) is pleased to announce its unaudited results for the fiscal year ended March 31, 2011.
The Company’s net sales, including a full 12-month period of results from the Company’s wholly-owned operating subsidiary, Kun Ming Xin Yuan Tang Pharmacies Co. Ltd. (XYT), for the year ended March 31, 2011 was $29 million, up 12.8% from XYT’s net sales in fiscal 2009. Net income, including a full 12-month period of results from XYT, remained flat, $2.7 million for fiscal 2010 compared to $2.8 million for only XYT’s net income in fiscal 2009. Net income was down primarily due to significant costs associated with the acquisition of XYT.
Company Chairman and CEO Mr. Zhen Jiang Wang notes, “We are very pleased that we generated sales of $29 million, exceeding our target by $2 million. We continue to expand largely due to our superior distribution and logistics strategy which permits us to outperform our competitors. With the advent of government mandates spurring growth opportunities directly into our markets, combined with the influx of foreign investment recently accepted in the healthcare sector, we consider ourselves perfectly positioned to capitalize on these unique synergies and as such, are highly optimistic and confident of our future.”
?